🔥 Wednesday 11 June 2025 Wed, 11 June 2025

Advance Metals has reported impressive initial diamond drilling results from its first hole at the Yoquivo Silver-Gold Project in Mexico, revealing multiple high-grade silver-gold zones that could expand the project's resource potential.

Articore Group reaffirms its FY25 financial guidance while initiating a strategic review to unlock shareholder value, coinciding with the appointment of Vivek Kumar as Group CEO.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Zip Co Limited has raised its FY25 cash EBTDA guidance to at least $160 million, driven by robust transaction growth in the US market exceeding 40% year-on-year in May 2025. The company also continues its share buy-back program amid steady credit performance.

Rapid Critical Metals is dramatically increasing its land position adjacent to the Webbs Silver Project, aiming to unlock new silver discoveries and expand existing resources with a significant exploration push.

West Coast Silver’s first two drill holes at Elizabeth Hill reveal exceptionally high-grade silver mineralisation starting from surface, confirming the project's near-term potential and setting the stage for expanded exploration.

European Lithium Ltd has released assay results from deep diamond drilling at Greenland’s Tanbreez Project, revealing high-grade rare earth mineralisation below the current resource estimate and setting the stage for resource expansion.

Pilbara Minerals Limited has announced a significant 2025 Mineral Resource update for its Pilgangoora Operation, increasing contained lithium oxide by 23% to 5.7 million tonnes and reinforcing its status as a global lithium powerhouse.

Perseus Mining outlines a robust five-year gold production plan targeting up to 2.7 million ounces with stable costs and strong cash margins, backed by major projects in Africa.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.